GEN - Genetic Engineering and Biotechnology News

Overcoming the VLP Purification Bottleneck

Integrated, process-savvy technologies are vital to overcoming the virus-like particles purification bottleneck.
Yahoo Finance

Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH

3 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces further investment in virus-like particle ...
FierceBiotech

Novavax's Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults

ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based ...
FierceBiotech

Icosavax raises $51M to take VLP RSV vaccine into humans

Icosavax has raised a $51 million series A round to take respiratory syncytial virus (RSV) vaccine IVX-121 through phase 1b in older adults. The vaccine is built on computationally designed ...
Yahoo Finance

Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

– No evidence of immune interference; initial indication of combinability achievable with company’s VLP technology – – Next steps: Icosavax plans to initiate a Phase 2 immunogenicity trial for IVX-A12 ...